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Functional Characterization of SAMD9, a Protein
Deficient in Normophosphatemic Familial
Tumoral Calcinosis
Dov Hershkovitz1,2, Yonit Gross2, Sagi Nahum2, Shiran Yehezkel3, Ofer Sarig4, Jouni Uitto5 and Eli Sprecher2,4
Dystrophic cutaneous calcinosis is associated with disorders as common as autoimmune diseases and cancer.
To get insight into the pathogenesis of this poorly understood process, we studied the function of SAMD9, a
protein of unknown function, recently shown to be deficient in a hereditary form of dystrophic calcification in
the skin, known as normophosphatemic familial tumoral calcinosis (NFTC). Consistent with the fact that in
NFTC severe inflammatory manifestations always precede cutaneous calcinosis, we found out that SAMD9 is
tightly regulated by interferon-g (IFN-g). In addition, the SAMD9 promoter was also found to respond strongly
to IFN-g in a luciferase reporter assay. Of interest, we identified a critical 30-bp fragment upstream to the SAMD9
transcription initiation site responsible for driving most of the gene expression. Bioinformatic analysis
suggested that SAMD9 function involves interaction with additional protein(s). Using the Ras recruitment
system assay and confirmatory immunoprecipitation, we demonstrated that SAMD9 interacts with RGL2.
To study the biological importance of this interaction, we assessed the effect of RNA interference-mediated
downregulation of this pair of proteins in various cell lines. We found out that downregulation of any of the two
protein partners caused increased expression of EGR1, a transcription factor with a known role in the regulation
of tissue calcification, inflammation, and cell migration. Supporting the physiological relevance of these data,
EGR1 levels were also upregulated in a fibroblast cell line derived from an NFTC patient. In conclusion, our data
indicate that SAMD9, an IFN-g-responsive protein, interacts with RGL2 to diminish the expression of EGR1, a
protein of direct relevance to the pathogenesis of ectopic calcification and inflammation.
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INTRODUCTION
Ectopic calcification is a pathological process that often
accompanies diseases as common as atherosclerosis, cancer,
and autoimmune diseases (Touart and Sau, 1998; Budoff
et al., 2007), and was found to represent an important
predictor of morbidity and mortality in the general population
(Chiu et al., 2010; Haas, 2010).
Acquired ectopic calcification in the skin is traditionally
classified into metastatic and dystrophic cutaneous calcinosis
(Touart and Sau, 1998; Sprecher, 2010). In metastatic
calcinosis, as seen in chronic renal failure, sarcoidosis,
or hyperparathyroidism, calcium deposits are the direct
consequence of elevated blood levels of calcium and/or
phosphate; in dystrophic calcinosis, typically associated with
autoimmune diseases such as scleroderma and dermatomyo-
sitis, as well as with atherosclerosis and cancer (Parwani
et al., 2004; Bai et al., 2009), the calcified material always
seems to accumulate subsequent to some form of primary
tissue damage.
The deciphering of the genetic basis of familial forms of
metastatic and dystrophic calcinosis cutis has recently
uncovered complex biochemical pathways involved in the
pathogenesis of ectopic calcification. The hereditary counter-
part of acquired disorders associated with metastatic calci-
fication is termed hyperphosphatemic familial tumoral
calcinosis; this was found to result from loss-of-function
mutations in one of the following three genes: FGF23,
encoding a potent phosphaturic protein, KL, encoding a co-
receptor for FGF23, and GALNT3, encoding a glycosyltrans-
ferase responsible for mediating a physiologically critical
post-translational modification of FGF23 (Topaz et al., 2004;
Benet-Pages et al., 2005; Ichikawa et al., 2007).
The inherited equivalent of dystrophic calcification is
termed normophosphatemic familial tumoral calcinosis
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(NFTC). Patients affected with this disease present with a
vasculitis-like rash at a young age, followed 3–7 years later by
the appearance of calcified masses in the cutaneous
and subcutaneous tissues (Topaz et al., 2006). Additionally,
these patients display severe inflammatory manifestations
in mucosal tissues, suggesting that the pathological basis of
their calcification involves abnormal regulation of inflamma-
tion. Recently, it has been shown that NFTC is the result of
biallelic loss-of-function mutations in the gene SAMD9
(Topaz et al., 2006).
SAMD9 encodes a 1,589 amino-acid protein with no
homology to known human proteins except for a paralog
protein termed SAMD9-like (SAMD9L) (Topaz et al., 2006; Li
et al., 2007). The fact that mutations in SAMD9 are associated
with profound inflammatory manifestations led us to inves-
tigate the effect of relevant mediators on SAMD9 expression.
We showed that tumor necrosis factor-a can induce SAMD9
expression and that both p38 and nuclear factor-kB regulate
tumor necrosis factor-a-mediated upregulation of SAMD9
(Chefetz et al., 2008). Independently, another group
also suggested that SAMD9 may function physiologically as
a tumor suppressor gene (Li et al., 2007), as both SAMD9
and SAMD9L were found to be overexpressed in desmoid
tumors transfected with wild-type adenomatous polyposis
coli protein. Overexpression of SAMD9 causes apoptosis and
reduced proliferation of malignant cells, whereas down-
regulation of SAMD9 is associated with increased
cellular proliferation and tumor growth both in in vivo and
in in vitro models (Li et al., 2007). Interestingly, deletion of a
genomic fragment on 7q21.3, spanning the SAMD9 gene, is
commonly found in cells from patients with myeloid
leukemia and myelodysplastic syndrome, suggesting again
that SAMD9 is an inhibitor of tumor progression (Asou et al.,
2009). Taken altogether, these data indicate that SAMD9
may have an important role in the pathogenesis of a wide
array of pathologies in humans, including ectopic calcifica-
tion, inflammation, and cancer, suggesting that this
protein may be of interest in the treatment of these diverse
ailments.
Despite these recent advances, little is currently known
about the molecular mechanisms underlying SAMD9’s mode
of action. In the present study, we provide evidence
indicating that SAMD9 may exert its effects in the context
of the interferon-g (IFN-g) signaling pathway.
RESULTS
IFN-c regulates SAMD9 expression
As summarized above, a steadily growing body of evidence
suggests that SAMD9 may have an important role in the
pathogenesis of inflammation and cancer (Topaz et al., 2006;
Li et al., 2007; Chefetz et al., 2008). As IFN-g is a cytokine
involved in both inflammation and cancer (Miller et al.,
2009), we studied its effect on SAMD9 expression. Using
quantitative real-time RT-PCR (QRT-PCR), we found that
SAMD9 transcript levels were upregulated in response to
IFN-g treatment by a factor of 2–2.5 (Figure 1a). Thus, two
inflammatory mediators associated with the pathogenesis of
inflammation and cancer, IFN-g and tumor necrosis factor-a
(Chefetz et al., 2008), seem to have an important role in the
regulation of SAMD9 expression.
To further investigate the molecular underpinning of the
regulation of SAMD9 expression by IFN-g, transient transfec-
tion assays were performed with a luciferase reporter
construct carrying various DNA fragments spanning up to
4 kb upstream to the putative SAMD9 transcription start site,
in the presence and absence of IFN-g. All constructs were
found to display increased luciferase activity as compared
with the empty vector. In addition, all constructs were found
to respond to IFN-g (Figure 2a). As SAMD9 was found by
QRT-PCR to be expressed strongly in transformed human
fibroblasts, but not in HeLa cells (Figure 1b), we compared its
promoter region activity in these two cell types. As shown
in Figure 2b, all constructs showed reduced luciferase activity
in HeLa cells as compared with human fibroblasts, further
supporting the physiological relevance of the luciferase
reporter assay system.
Identification of IFN-c-responsive elements within the
SAMD9 promoter
Using a transcription element search software (http://www.
cbil.upenn.edu/cgi-bin/tess/tess), we carefully scrutinized the
SAMD9 promoter region for candidate transcription element
binding sites. Deletion constructs were designed to evaluate
the role of these transcription elements in SAMD9 regulation.
We found out that most of the IFN-g-responsive SAMD9
promoter activity resides within a short 30-bp stretch
spanning positions 89 to 118 upstream to the SAMD9
transcription start site (Figure 3a). Deletion of this fragment
was found to almost completely abolish the promoter
activity. In addition, this fragment alone was able to sustain
the IFN-g-responsive promoter activity to the same level as
the largest upstream fragment assayed.
Bioinformatic analysis revealed the existence of two
transcription factor binding sites within this minimal 30-bp
fragment, one for IFN regulatory factor 1 (IRF-1) located on
the positive strand and the other for IFN stimulated response
element located on the negative strand (Figure 3b). This
30-bp fragment caused a band shift when incubated with the
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Figure 1. Effect of IFN-c and cell type on SAMD9 expression. (a) Human
fibroblasts were exposed to 10 ngml–1 of IFN-g or its vehicle for 24 hours, and
SAMD9 expression was measured as described in Materials and Methods.
Results are expressed as fold change of expression relative to cells treated with
vehicle±SD. (b) SAMD9 expression was measured as described in Materials
and Methods in various cell lines. Results are expressed as fold change of
expression relative to the levels measured in HeLa cells±SD.
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nuclear extract derived from transformed human fibroblasts,
indicating that it is actually a transcription factor binding
sequence (Figure 3c). Incubation of the same probe with the
nuclear extract derived from HeLa cells generated a weaker
band, as expected given the reduced expression of SAMD9
in this cell line. We then used the TFSEARCH software
(http://molsun1.cbrc.aist.go.jp/research/db/TFSEARCH.html)
to identify potentially deleterious point mutations capable
of abolishing the transcription factor-binding capacity of
the critical 30-bp fragment. As predicted, introduction of
these mutations within the 30-bp fragment resulted in the
disappearance of the band in the band shift assay (Figure 3c),
lending further support to the importance of this minimal
region for IFN-g-dependent regulation of SAMD9 expression.
SAMD9 interacts with RGL2
To get further insight into the mechanism of action of
SAMD9, we aimed at identifying proteins interacting with
SAMD9. For that purpose, we used the Ras recruitment
system (Broder et al., 1998; Aronheim, 2001). We chose to
screen a cDNA expression library derived from human
spleen, given the high level of expression of SAMD9 in
this tissue (Li et al., 2007). The SAM domain-containing
N-terminal part of SAMD9 was fused in frame with a cDNA
encoding the cytoplasmic Ras protein (Holmberg et al., 2002)
under the control of the Met425 promoter and served as a
bait. The library was composed of cDNAs fused to the v-Src
myristoylation signal under the control of the Gal1 promoter
(Hubsman et al., 2001). A Cdc25-2 yeast strain was
cotransfected with the bait and prey library expression
constructs, and selected on glucose plates lacking uracil
and leucine. Transformants were replica plated into galac-
tose-containing medium lacking methionine and grown at the
restrictive temperature of 36 1C. Yeast colonies growing
under these conditions were selected and further analyzed.
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Figure 2. Analysis of SAMD9 promoter. Different DNA fragments of the
putative SAMD9 proximal promoter were cloned into pGL3 promoter-
luciferase (LUC) vector and assayed for luciferase activity as described in
Materials and Methods. The locations of the various cloned fragments are
given as the position of the nucleotide boundaries (relative to the transcription
start site). (a) The constructs were assayed in the presence (þ IFNg) or absence
( IFNg) of IFN-g (10 ngml–1), as well as (b) in human fibroblasts and HeLa
cells, two cell lines known to express different levels of SAMD9 transcripts.
Results are expressed as mean relative luciferase activity±SD.
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Figure 3. Characterization of a 30-bp IFN-c-responsive element within the
SAMD9 promoter region. (a) Deletion fragments were used to identify a
minimal promoter element between bases 89 and 118 (upstream to the
transcription start site) that conferred responsiveness to IFN-g. The various
DNA fragments were cloned into pGL3 promoter-luciferase (LUC) vector and
assayed for luciferase activity as described in Materials and Methods. The
constructs were assayed in the presence (þ IFNg) or absence ( IFNg) of
IFN-g (10 ngml–1). Results are expressed as mean relative luciferase
activity±SD. (b) Schematic representation of the designed radio-labeled
probe spanning part of the critical IFN-g-responsive element within the
SAMD9 promoter, including the predicted transcription factor recognition
sites of IRF-1 and IFN stimulated response element. In addition to the wild-
type probe, we generated a probe carrying two A4T transversions at positions
98 and 105, predicted to abolish the activity of the two predicted
transcription factor recognition sites (arrowheads). (c) incubation of the wild-
type, labeled 30-bp probe with nuclear protein extract from EaHy (lane 2) and
HeLa (lane 3) cell lines caused a band shift compared with the probe that was
made to run without previous incubation with nuclear extracts (lane 1). Note
that the prominent band (arrow) is more apparent in EaHy cells compared
with HeLa cells, in accordance with the differential expression of SAMD9 in
these two cell lines. The prominent band (arrow) was not visible anymore
when the mutant probe was incubated with the nuclear extracts (lanes 4–6).
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Plasmid DNA was isolated from the clones and reintroduced
into the Cdc25-2 yeast strain with either the specific
pMet425-Ras-SAMD9-NT bait or a nonspecific bait.
cDNAs conferring to yeast transformants the ability to grow
specifically with pMet425-Ras-SAMD9-NT bait at the
restrictive temperature, but not with the nonspecific bait,
were subsequently characterized by direct DNA sequencing.
Out of eight such clones, seven separate clones were
found to encode the 131-amino-acid C-terminal part of
RGL2 (gene accession number NM_004761.2), whereas one
additional clone encoded the 119-amino acid C-terminal part
of RALGDS (gene accession number NM_001042368.1).
Both RGL2 and RALGDS showed specific interaction with
SAMD9 after reintroduction into the yeasts (Figure 4a). RGL2
and RALGDS are two related proteins that function as Ras
effectors, and were shown to be involved in in vivo
carcinogenesis (Gonzalez-Garcia et al., 2005) and in the
immune response to viral infections (Chien et al., 2006).
To validate the above findings, we used coimmunopreci-
pitation. The RGL2 C-terminal part fused to an hemagglutinin
(HA) tag could immunoprecipitate the SAMD9 N-terminal
fragment fused to Myc tag. No such interaction could be
demonstrated between the N-terminal part of SAMD9 and
RALGDS (Figure 4b).
SAMD9 and RGL2 suppress EGR1 expression
To ascertain the consequences of SAMD9’s interaction
with RGL2, we compared global gene expression patterns
in cell lines downregulated using specific siRNAs for these
two genes. RGL2 downregulation caused upregulation of
11 genes and downregulation of 5 genes by a factor of 2-fold
or more. Downregulation of SAMD9 caused an increase in
the expression of eight genes (Supplementary Table S1
online). Using QRT-PCR, we found out that one such gene
was upregulated following cell transfection with either type
of siRNA: EGR1, which encodes the transcription factor early
growth response gene-1 (Figure 5a). EGR1 exhibited a more
than 4-fold increase in expression following downregulation
of SAMD9 or RGL2.
Consistent with the above findings, EGR1 levels were
3-fold upregulated in fibroblasts derived from an NFTC
patient carrying a loss-of-function mutation in SAMD9 (Topaz
et al., 2006) as compared with control fibroblasts (Figure 5b).
Additionally, we were able to show that the inhibitory effect
of RGL2 on EGR1 expression is SAMD9 dependent. Indeed,
downregulation of RGL2 caused an increase in EGR1 RNA
levels in endothelial cells, expressing high levels of SAMD9.
On the other hand, no effect of RGL2’s downregulation on
EGR1 RNA levels was seen in Hela cells expressing SAMD9
at a considerably lower level (Figure 5c). These findings
underscore the physiological relevance of SAMD9’s interac-
tion with RGL2 for EGR1 regulation.
DISCUSSION
Mendelian disorders have been recently re-discovered as a
unique tool for the delineation of novel biological functions
(Antonarakis and Beckmann, 2006). As NFTC is character-
ized by severe inflammation and ectopic calcification (Topaz
et al., 2006), the fact that SAMD9 is defective in this disorder
suggests that this protein may have a role in the regulation of
both processes (Topaz et al., 2006). Additionally, several
laboratory studies suggest that SAMD9 might have a role as a
tumor suppressor gene as well (Li et al., 2007; Asou et al.,
2009), although no increased incidence of cancerous
conditions has been reported among NFTC patients. The
purpose of the present work was to further characterize the
mode of action of SAMD9.
We initially assessed the effect of IFN-g on SAMD9
expression, as IFN-g has been shown to be involved in the
pathogenesis of both cancer and inflammation. We could
demonstrate that IFN-g treatment induces the expression of
SAMD9 in both endothelial cells and fibroblasts. Very
recently, it was found that glioblastoma cell lines show an
increase in SAMD9 expression following treatment with type
1 IFNs or incubation with inactivated Sendai virus particle
(HVJ-E), suggesting that SAMD9 might have a role in the
protection against viral infection (Tanaka et al., 2010). Taken
together with the fact that SAMD9 responds to tumor necrosis
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Figure 4. SAMD9 interacts with RGL2. (a) To identify SAMD9’s potential
partners, we screened a spleen cDNA library using the Ras recruitment
system. Cotransfection with pMet425-Ras-SAMD9NT and pMyr expression
plasmid encoding either RALGDS or RGL2 myristoylated prey fusion protein
resulted in yeast proliferation (left panel). There was no growth in replicate
plates in which pMet425-Ras-SAMD9NT promoter was inactivated (Gal-LU),
pMyr-RGL2/pMyr-RALGDS promoter was inactivated (Glu-MUL), or both
were inactivated (YPD), indicating the specificity of the interaction
(right panel). (b) The interaction with RGL2 was further validated using
coimmunoprecipitation. HEK-293T cells were cotransfected with pCAN-Myc-
SAMD9 and either pcDNA-RGL2-HA or pcDNA-RALGDS-HA. Cell lysate
was coimmunoprecipitated with anti-HA and eluted proteins were separated
by 10% SDS-PAGE, followed by western blotting and probed with anti-Myc.
Total cell lysates of transfected HEK-293T are shown in the lower panel.
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factor-a treatment (Chefetz et al., 2008), these data position
SAMD9 at an important crossroad between major inflamma-
tory pathways. It is worth noting that the SAMD9 paralog,
SAMD9L, can also be induced by treatment with type 1 IFNs
(Pappas et al., 2009).
Analysis of SAMD9 promoter revealed the existence of a
short DNA fragment comprising an IRF-1 transcription factor
response element, capable of regulating SAMD9 expression.
IRF-1 is a member of a large family of proteins that function
as transcription activators of genes induced by IFN a, b, and g
(Schmitz et al., 2007). IRF-1 is an important mediator of
apoptosis (Gao et al., 2010) and may have a role in apoptosis
induced by SAMD9, as demonstrated in colon cancer cells
(Li et al., 2007). There is also ample evidence that IRF-1
functions as a tumor suppressor gene. For example, IRF-1
gene repression is essential for the malignant transformation
of hepatitis C virus-infected cells (Zekri et al., 2010); loss of
heterozygosity in gastric cancer often involves the IRF-1 gene
(Gao et al., 2010); and IRF-1 expression is markedly
decreased in esophageal squamous cell carcinoma (Wang
et al., 2007).
Our findings suggest that IRF-1 tumor suppressor activity
may in part result from its inductive effect on SAMD9
expression. In addition, in several studies myelodysplastic
syndrome and leukemia have been linked to both SAMD9
and IRF-1 (Liebermann and Hoffman, 2006; Maratheftis et al.,
2006; Asou et al., 2009). Inactivation of IRF-1 is commonly
found in myelodysplastic syndrome and leukemia
(Liebermann and Hoffman, 2006; Maratheftis et al., 2006).
Interestingly, in these same malignancies, a common micro-
deletion in chromosome 7q21.3, harboring the SAMD9
locus, has been described (Asou et al., 2009). Moreover,
autoimmune manifestations, which are the hallmark of
NFTC, are commonly found in myelodysplastic syndrome
patients and their pathogenesis is mediated by IRF-1 (Pinheiro
et al., 2009).
The SAMD9 protein contains a conserved sterile a-motif
(SAM) domain. These domains usually serve as protein
interaction domains. In the present case, we found that this
domain interacts with the C-terminal part of RGL2. RGL2 is a
guanine nucleotide exchange factor that, following activation
by GTP-bound Ras, can activate two Ral family members,
RalA and RalB (Ferro and Trabalzini, 2010). RalB, the direct
downstream target of RGL2, has been shown to have a role in
cancer (Chien and White, 2003) and in response to viral
infections (Cho et al., 2006) just as SAMD9 (Tanaka et al.,
2010).
Both SAMD9 and RGL2 seem to function by inhibiting
EGR1 expression. In addition, the inhibitory activity of RGL2
seems to be dependent upon the expression of SAMD9, as it
is not detectable in HeLa cells, which are naturally deficient
in SAMD9. EGR1 is overexpressed in atherosclerosis in
humans as well as mouse models (McCaffrey et al., 2000).
A more recent report showed that EGR1 is an important
mediator of interleukin-13-induced inflammation as well
(Cho et al., 2006). Interestingly, EGR1 was also found to
regulate wound healing in a model of scleroderma, an
autoimmune disease, which is commonly associated with
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Figure 5. SAMD9 and RGL2 regulate EGR1 expression. (a) Human fibroblasts
were transfected with SAMD9 (siSAMD9)- and RGL2 (siRGL2)-specific
siRNA, as well as control siRNA. After 48 hours, RNA was extracted and
SAMD9 (black columns), RGL2 (gray columns), and EGR1 (white columns)
expression levels were measured as described in Materials and Methods.
Results are expressed as fold change of expression relative to cells treated with
control siRNA±SD. (b) RNA was extracted from transformed human
fibroblasts derived from a healthy individual (WT fibroblasts) and from a
patient with normophosphatemic familial tumoral calcinosis (NFTC)
(NFTC fibroblasts). EGR1 expression was measured as described in Materials
and Methods. Results are expressed as fold change of expression in NFTC
relative to normal cells±SD. (c) EaHy and HeLa cells were transfected with
an RGL2-specific siRNA, as well as control siRNA. After 48 hours, RNA was
extracted and EGR1 expression was measured as described in Materials
and Methods. Results are expressed as fold change of expression relative
to cells treated with control siRNA±SD. WT, wild type.
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ectopic calcification (Wu et al., 2009). In another study,
EGR1 was found to be the only single gene that was
differentially expressed in transforming growth factor-b-
treated fibroblasts derived from scleroderma patients as
compared with normal fibroblasts (Sargent et al., 2010).
Moreover, tissue deposition of calcium phosphate has been
associated with increased EGR1 expression (Molloy and
McCarthy, 2006). EGR1 has been linked to non-cutaneous
inflammatory disorders as well. In Crohn’s disease, another
autoinflammatory disorder, EGR1 levels are elevated and,
interestingly, RGL2 is downregulated (Fernandez-Becker and
Moss, 2009), exactly as in our system.
EGR1 has also been implicated in the pathogenesis of
breast, prostate, and lung cancer (Gitenay and Baron, 2009;
Fang et al., 2010; Redmond et al., 2010). Apparently, EGR1 is
also pivotal for cancer metastasis, as it was downregulated in
a clone from a highly metastatic fibrosarcoma cell line that
lost its metastatic capacity (Cermak et al., 2010). Metastatic
potential was restored following introduction of exogenous
EGR1 to the cells (Cermak et al., 2010). One component of
the pro-metastatic phenotype induced by EGR1 is the
activation of genes that control actin contractility (Cermak
et al., 2010). Of interest, we could demonstrate intracellular
redistribution of actin filaments following downregulation of
SAMD9 or RGL2 (not shown), which was shown to increase
EGR1 expression.
In summary, the present data indicate that SAMD9, a
molecule associated with the regulation of cutaneous
inflammation, ectopic calcification in the skin, and possibly
oncogenesis, seems to function along the IFN-g signaling
pathway and regulates, in concert with RGL2, the expression
of EGR1, a key mediator of inflammation in health and
disease (Figure 6).
MATERIALS AND METHODS
Reagents and antibodies
The following antibodies were used: anti-Myc monoclonal (9E10)
and anti-HA monoclonal (12CA5). IFN-g was obtained from
PeproTech (Rocky Hill, NJ). SAMD9-specific (50-CAAAGCAACCAA
UUGCAUA-30 (dT)) and RGL2-specific siRNA (50-CUAAUGUAUUC
UACGCCAU-30 (dT)), as well as universal control siRNA, were
purchased from Sigma-Aldrich (St Louis, MO).
Plasmids and expression constructs
pGL3 promoter luciferase reporter plasmid (Promega, Madison, WI)
was used to insert PCR-amplified MluI–XhoI DNA fragments
spanning the different parts of the putative proximal SAMD9
promoter between nucleotide positions 4306 and 67 SAMD9
(relative to the transcription start site). The primers used in these
experiments are provided in Supplementary Table S2 online.
A DNA sequence encompassing the SAMD9 SAM domain
(amino acids 1–124) was cloned into pMet425-Ras to generate
pMet425-Ras-SAMD9-NT, which was then digested using BamHI
and XhoI and the insert was subcloned into the mammalian
expression plasmid pCAN to generate Myc-tagged SAMD9. The
spleen library plasmids expressing RALGDS and RGL2 were digested
using EcoRI and XhoI and subcloned into pcDNA-3HA plasmid to
generate 3HA-tagged pcDNA-RALGDS and pcDNA-RGL2 plasmids.
Cell cultures and transient transfections
Fibroblasts transformed with a pBABE-H2AGFP construct
containing the human telomerase gene, EaHy926 cells, a human
umbilical vein endothelial cells-derived transformed endothelial cell
line, human embryonic kidney 293T (HEK-293T) and HeLa cells
were maintained in DMEM containing 10% FCS and 1% peni-
cillin and streptomycin and grown at 37 1C and 5% CO2.
The medium of EaHy926 cells was supplemented with 2%
hypoxanthine-aminopterin-thymidine (Biological Industries, Beit
Haemek, Israel).
Cells were transfected with the appropriate expression plasmid or
siRNA using lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruction. Fresh
medium was added 4–5 hours after transfection and cells were
harvested 48hours after transfection.
QRT-PCR
For QRT-PCR validation of global gene expression results, cDNA
was synthesized from 1mg of total RNA using the Verso cDNA kit
(Thermo Scientific, Surrey, UK) and random hexamers. cDNA PCR
amplification was carried out using the SYBR Green JumpStart Taq
ReadyMix (Sigma, St Louis, MO) on an Mx3000p/5p multifilter
system (Stratagene, Cedar Creek, TX) with gene-specific intron-
crossing oligonucleotide pairs listed in Supplementary Table S3
online. To ensure the specificity of the reaction conditions, at the
end of the individual runs, the melting temperature of the amplified
products was measured to confirm its homogeneity. Cycling
conditions were as follows: 95 1C for 10minutes, 95 1C for
10 seconds, 62 1C for 25 seconds, and 72 1C for 15 seconds for a
total of 40 cycles. Each sample was analyzed in duplicate. For
quantification, standard curves were obtained using serially diluted
cDNA amplified in the same RT-PCR run. Results were normalized
to ACTB mRNA levels.
SAMD9 EGR1
RGL2
IRF-1
IFN-γ
TNF-α
Figure 6. Schematic representation of SAMD9 regulation and downstream
effect. Previous (Chefetz et al., 2008) and current data indicate that SAMD9
expression is tightly regulated by the inflammatory cytokines TNF-a and
IFN-g. Our results suggest that this regulation is mediated in the case of TNF-a
by p38 and NF-kB (Chefetz et al., 2008), and in the case of IFN-g through the
IRF-1 transcription factor. Additionally, SAMD9 may regulate inflammation,
calcification, and cancer progression through its effect on EGR1 expression, in
concert with its partner, RGL2. IFN-g, interferon-g; IRF-1, IFN regulatory
factor-1; NF-kB, nuclear factor-kB; TNF-a, tumor necrosis factor-a.
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Promoter activity assay
The luciferase constructs were transfected into fibroblasts using
lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. At 48 hours after transfection, the protein was extracted
and assayed for luciferase activity using the Dual Luciferase Reporter
Assay System (Promega) according to the manufacturer’s instruc-
tions. Relative luminometer units were read using a TD-20/20
luminometer (Turner Designs, Sunnyvale, CA).
Electrophoretic mobility shift assay
Nuclear extraction was performed as previously described (Schreiber
et al., 1989), except that the buffers included Protease Inhibitor
Cocktail (Sigma-Aldrich). Electrophoretic mobility shift assay was
performed with nuclear extracts from EaHy and HeLa cell lines. The
lysates were incubated in binding buffer (25mM HEPES (pH 7.9),
150mM KCl, 2% glycerol, 5mM dithiothreitol, and 1mg of poly
(dI-dC)) for 5minutes at room temperature, and 32P-labeled
oligonucleotide probes were added (15,000 c.p.m.). After 20
minutes of incubation, the samples were resolved on a 6%
nondenaturing polyacrylamide gel in 0.53 TBE buffer and auto-
radiographed. The 32P-end-labeled DNA probes used spanned
nucleotide positions from 118 to 89 (Supplementary Table S2
online) and the same probe carrying A4T transversions at positions
98 and 105.
Ras recruitment system
pMet425-Ras-SAMD9-NT was used as a bait to screen a human
spleen expression library. Yeast growth, transfection, and screening
protocol were performed as described in Hubsman et al. (2001).
Coimmunoprecipitation
At 24 hours after transfection with pCAN-Myc-SAMD9 and pcDNA-
RALGDS-3HA, pcDNA-RGL2-3HA, or pcDNA-3HA, HEK-293T
cells were lysed in whole cell extract buffer (25mM HEPES, pH
7.7, 0.3 M NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.1% Triton X-100,
0.5mM DTT, 20mM-glycerolphosphate, 0.1mM Na2VO4, 100 gml
–1
phenylmethylsulfonyl fluoride, protease inhibitor cocktail 1:100;
Sigma-Aldrich). Anti-HA monoclonal antibodies were incubated
overnight at 4 1C with 400–600mg of the HEK-293T protein extract.
Protein A Sepharose beads (Sigma Chemical, St Louis, MO) were
added to the extracts for 1 hour at 4 1C. After four washes with whole
cell extract buffer, the precipitated proteins were eluted using
SDS-PAGE sample buffer. Samples were boiled for 3minutes and
the proteins were then separated by 10% SDS-PAGE, followed by
transfer to a nitrocellulose membrane. Blots were blocked in 5% dry
milk in PBS and washed three times for 5minutes in PBS. Proteins
were detected using antibodies against Myc diluted 1:500.
Global gene expression analysis
An amount of 200 ng of total RNA was amplified into cRNA and
biotinylated by in vitro transcription using the Illumina TotalPrep
RNA Amplification Kit (Ambion, Austin, TX) according to the
manufacturer’s protocol. Biotinylated cRNA was purified, fragmen-
ted, and subsequently hybridized to an Illumina Human HT-12 v3
BeadChip (Direct Hybridization assay, Illumina, San Diego, CA).
The hybridized chip was stained with streptavidin-Cy3 (Amersham,
Arlington Heights, IL) and scanned with an Illumina bead array
reader. The scanned images were imported into GenomeStudio
(Illumina) for data extraction and quality control. Statistical analysis
of gene expression in the different treatments was done on the raw
bead-level data. The different treatment modalities were compared
using one-way analysis of variance test with the SPSS 12.0 software
(Chicago, IL). Differences between treatments that were more than
2-fold and with a P-value of less than 0.001 were considered
significant.
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